CuATSM
CuATSM结构式
|
常用名 | CuATSM | 英文名 | CuATSM |
|---|---|---|---|---|
| CAS号 | 68341-09-3 | 分子量 | 321.91 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C8H14CuN6S2 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | N/A |
|
Zn II(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism.
Neurobiol. Dis. 81 , 20-4, (2015) Mutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effective therapeutics do not yet exist. Transgenic rodent models b... |
|
|
Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis.
J. Neurosci. 34(23) , 8021-31, (2014) Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and an expression level-dependent phenotype in transgenic rodents. We show that oral treatment with the therapeutic agent diacetyl-bis(4-met... |
|
|
Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.
Amyotroph. Lateral Scler. Frontotemporal Degener. 14(7-8) , 586-90, (2013) Our objective was to assess the copper(II) complex of diacetylbis(4-methylthiosemicarbazone) [Cu(II)(atsm)] for its preclinical potential as a novel therapeutic for ALS. Experimental paradigms used were designed to assess Cu(II)(atsm) efficacy relative to tre... |